Karolinska Development
1,53 SEK 0%1 investor følger denne virksomhed
Karolinska Development is a Nordic investment company in the life science sector. The company focuses on identifying medical innovations to create and develop companies that further develop such innovations into differentiated products. Karolinska Development's portfolio consists of a number of companies focused on developing treatment methods for diseases that are classified as life-threatening and serious. The largest business operations are in the Nordic market.
Omsætning
-
EBIT %
-
P/E
76,5
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
KDEV
Daglig lav / høj pris
1,5 / 1,57
SEK
Markedsværdi
413,22 mio. SEK
Aktieomsætning
340,16 t SEK
Volumen
222 t
Finanskalender
Delårsrapport
30.08.2024
Delårsrapport
15.11.2024
Årsrapport
14.02.2025
Delårsrapport
30.04.2025
Generalforsamling
15.05.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
invoX Pharma Ltd | 47,7 % | 43,9 % |
Worldwide International Investments Ltd | 10,4 % | 9,6 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
Karolinska Development’s portfolio company Umecrine Cognition secures funding for continued clinical development of golexanolone
Karolinska Development’s portfolio company Biosergen gets final approval to test lead candidate BSG005 in patients with invasive fungal infection
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools